Refine Search
(0)
(2)
(2)
(3)

Thrombotic Diseases

The reports provide a detailed assessment of current treatment paradigms, primary research-based analysis of the dynamics driving treatment choices, competitive evaluation of marketed drugs and the late-stage development pipeline, discussion of the level of opportunity today and in 10 years, and estimated current and future market value.

Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

  • $10,995
  • July 2018
Add to Basket Quick View Add to Saved List

Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrien...

Acute Coronary Syndrome: Competitive Landscape to 2026

  • $3,495
  • June 2018
Add to Basket Quick View Add to Saved List

Acute coronary syndrome (ACS) refers to a spectrum of myocardial ischemic states caused by the disruption of atherosclerotic plaques in the coronary arteries. The syndrome is precipitated by coronary artery occlusion (stenosis), which results i...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • June 2017
Add to Basket Quick View Add to Saved List

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality a...

PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • August 2016
Add to Basket Quick View Add to Saved List

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will r...